Revenue: As of FY2026 Q2, the actual value is USD 0, meeting the estimate of USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.11, beating the estimate of USD -0.125.

EBIT: As of FY2026 Q2, the actual value is USD -10.31 M.

Financial Highlights for aTyr Pharma, Inc.

Cash and Investment Position

As of June 30, 2026, cash, cash equivalents, restricted cash, and available-for-sale investments totaled $58,913 thousand, a decrease from $80,922 thousand as of December 31, 2025. The company anticipates this cash position will be sufficient to fund current operations into late 2028.

Operating Expenses

Three Months Ended June 30

• Research and Development (R&D) Expenses: R&D expenses were $6,748 thousand for the second quarter of 2026, a decrease from $15,384 thousand in the second quarter of 2025.
• General and Administrative (G&A) Expenses: G&A expenses were $4,133 thousand for the second quarter of 2026, down from $4,929 thousand in the second quarter of 2025.
• Total Operating Expenses: Total operating expenses for the second quarter of 2026 were $10,881 thousand, compared to $20,313 thousand for the same period in 2025.

Six Months Ended June 30

• Research and Development (R&D) Expenses: R&D expenses were $14,065 thousand for the six months ended June 30, 2026, a decrease from $27,198 thousand for the same period in 2025.
• General and Administrative (G&A) Expenses: G&A expenses were $8,252 thousand for the six months ended June 30, 2026, compared to $8,888 thousand for the same period in 2025.
• Total Operating Expenses: Total operating expenses for the six months ended June 30, 2026, were $22,317 thousand, down from $36,086 thousand for the same period in 2025.

Loss from Operations

• Three Months Ended June 30: Loss from operations was -$10,881 thousand in the second quarter of 2026, an improvement from -$20,313 thousand in the second quarter of 2025.
• Six Months Ended June 30: Loss from operations was -$22,317 thousand for the six months ended June 30, 2026, compared to -$36,086 thousand for the same period in 2025.

Total Other Income (Expense), net

• Three Months Ended June 30: Total other income (expense), net, was $571 thousand in the second quarter of 2026, compared to $781 thousand in the second quarter of 2025.
• Six Months Ended June 30: Total other income (expense), net, was $1,215 thousand for the six months ended June 30, 2026, compared to $1,673 thousand for the same period in 2025.

Consolidated Net Loss

• Three Months Ended June 30: Consolidated net loss was -$10,310 thousand in the second quarter of 2026, an improvement from -$19,532 thousand in the second quarter of 2025.
• Six Months Ended June 30: Consolidated net loss was -$21,102 thousand for the six months ended June 30, 2026, compared to -$34,413 thousand for the same period in 2025.

Net Loss Attributable to aTyr Pharma, Inc.

• Three Months Ended June 30: Net loss attributable to aTyr Pharma, Inc. was -$10,309 thousand in the second quarter of 2026, compared to -$19,531 thousand in the second quarter of 2025.
• Six Months Ended June 30: Net loss attributable to aTyr Pharma, Inc. was -$21,100 thousand for the six months ended June 30, 2026, compared to -$34,411 thousand for the same period in 2025.

Operational Metrics and Restructuring

aTyr Pharma, Inc. implemented a corporate restructuring, including a workforce reduction of approximately 60%, to align resources with its efzofitimod program. This restructuring and additional cost-saving measures are expected to reduce annualized operating expenses by approximately $13 million, starting in the fourth quarter of 2026.

Outlook and Guidance

aTyr Pharma, Inc. is awaiting feedback from the FDA by the end of August 2026 on the protocol for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis. Topline results from the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD are anticipated in the first quarter of 2027. The company will require additional capital through various financing means to fund the future development of efzofitimod in the planned Phase 3 study.